Bausch + Lomb (BLCO) Expected to Announce Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is expected to post its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of $0.35 per share and revenue of $1.3834 billion for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 8:00 AM ET.

Bausch + Lomb Price Performance

NYSE BLCO opened at $17.11 on Wednesday. The firm has a market capitalization of $6.06 billion, a P/E ratio of -19.67, a P/E/G ratio of 0.98 and a beta of 0.61. The company has a current ratio of 1.51, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76. The firm’s fifty day simple moving average is $16.98 and its two-hundred day simple moving average is $15.69. Bausch + Lomb has a 12-month low of $10.45 and a 12-month high of $17.86.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds have recently made changes to their positions in BLCO. Northwestern Mutual Wealth Management Co. boosted its position in Bausch + Lomb by 729.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after purchasing an additional 2,042 shares during the period. Focus Partners Wealth acquired a new stake in shares of Bausch + Lomb during the third quarter worth approximately $170,000. JPMorgan Chase & Co. acquired a new position in Bausch + Lomb during the 2nd quarter worth $200,000. Lido Advisors LLC acquired a new stake in shares of Bausch + Lomb in the 4th quarter valued at about $299,000. Finally, Jump Financial LLC bought a new stake in Bausch + Lomb in the second quarter valued at about $313,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on BLCO. JPMorgan Chase & Co. raised their price objective on shares of Bausch + Lomb from $13.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Citigroup upgraded Bausch + Lomb from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Thursday, December 11th. Wells Fargo & Company increased their price objective on shares of Bausch + Lomb from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bausch + Lomb in a report on Wednesday, January 21st. Finally, Raymond James Financial reissued an “outperform” rating and issued a $19.00 target price (up previously from $18.00) on shares of Bausch + Lomb in a research report on Thursday, October 30th. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $17.42.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.